Inefficiency of renin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart

Minerva Cardioangiologica

Volumn 55, Issue 3, 2007, Pages 311-315

  Fazio, G ^a,b   Pizzuto, C ^a   Sutera, L ^a   Guttilla, D ^a   Di Gesaro, G ^a   Cascio, C ^a   Novo, G ^a   Assennato, P ^a   Novo, S ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NONE   (Italy)

Author keywords

Angiotensin converting enzyme inhibitors; Atrial fibrillation; Heart

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROPHYLAXIS; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; DRUG THERAPY, COMBINATION; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES;

EID: 34447540172     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation 2002;106:331-6.
2. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Eur Heart J 2003;24:2090-8.
3. Healey JS, Baranchuk A, Crystal E, Morillo CA, Gurfinkel M, Yusuf S et al. Prevention of fibrillation atrial with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. A meta-analysis. J Am Coll Cardiol 2005;45:1832-9.
4. Kalus JS, Coleman CI, White CM. The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol 2006;46:21-8.
5. Dilaveris P, Giannopoulos G, Synetos A, Stefanadis C. The role of renin angiotensin system blockade in the treatment of atrial fibrillation. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:387-403.
6. Yamagishi S, Takenaka K, Inoue H. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Med Hypotheses 2006;66:118-20.
7. Boos CJ, Lip GY. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens 2005;19:855-9.
8. Pedersen OD, Kober L, Torp-Pedersen C. Atrial fibrillation and atrial cardiomyopathy - two sides of the same coin? Am Heart J 2004;147:953-5.
9. Korantzopoulos P, Kolettis T, Kountouris E, Siogas K. Atrial remodeling in persistent atrial fibrillation: the potential role of aldosterone. Eur Heart J 2004;25:1086; author reply 1086-7.
10. Freestone B, Beevers DG, Lip GY. The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target? J Hum Hypertens 2004;18:461-5.
11. Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am J Cardiol 2003;91 Suppl 10A:28G-34G.
12. Klein HU, Goette A. Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation? J Am Coll Cardiol 2003;18:2205-6.
13. Blann AD, Nadar S, Lip GY. Pharmacological modulation of platelet function in hypertension. Hypertension 2003;42:1-7.
14. Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003;91 Suppl 6AT5D-26D.
15. Zimmermann M, Unger T. Challenges in improving prognosis and therapy: the ongoing telmisartan alone and in combination with ramipril global end point trial programme. Expert Opin Phermacother 2004;5:1201-8.
16. Liu T, Li GP. ACEIs and ARBs may reduce incidence of atrial fibrillation by their anti-inflammatory characteristics. Med Hypotheses 2006;66:437.
17. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2006;47:889-90; author reply 890-1.